Cargando…

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond

Immunoglobulin light chain amyloidosis (AL amyloidosis) is a rare systemic disease characterized by monoclonal light chains (LCs) depositing in tissue as insoluble fibrils, causing irreversible tissue damage. The mechanisms involved in aggregation and deposition of LCs are not fully understood, but...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roccatello, Dario, Fenoglio, Roberta, Sciascia, Savino, Naretto, Carla, Rossi, Daniela, Ferro, Michela, Barreca, Antonella, Malavasi, Fabio, Baldovino, Simone
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312896/ https://www.ncbi.nlm.nih.gov/pubmed/32531894 http://dx.doi.org/10.3390/ijms21114129

Ejemplares similares

Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience
por: Roccatello, Dario, et al.
Publicado: (2020)

The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents
por: Roccatello, Dario, et al.
Publicado: (2017)

Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy
por: Roccatello, Dario, et al.
Publicado: (2022)

Renal involvement as a unique manifestation of hemophagocytic syndrome
por: Roccatello, Dario, et al.
Publicado: (2022)

Focal segmental glomerular sclerosis can be effectively treated using an intensive B-cell depletion therapy
por: Roccatello, Dario, et al.
Publicado: (2022)

Recognizing the new disorder “idiopathic hypocryoglobulinaemia” in patients with previously unidentified clinical conditions
por: Roccatello, Dario, et al.
Publicado: (2022)

The “4 plus 2” rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study
por: Roccatello, Dario, et al.
Publicado: (2017)

The steroid-sparing effects of a mycophenolate mofetil-based regimen in the management of immunoglobulin A nephropathy in patients with histologically active lesions: A comparison with a control cohort receiving conventional therapy
por: Roccatello, Dario, et al.
Publicado: (2023)

Non HCV-Related Mixed Cryoglobulinemic Vasculitis With Biopsy-Proven Renal Involvement: The Effects of Rituximab
por: Fenoglio, Roberta, et al.
Publicado: (2022)

A Prospective Study on Long-Term Clinical Outcomes of Patients With Lupus Nephritis Treated With an Intensified B-Cell Depletion Protocol Without Maintenance Therapy
por: Roccatello, Dario, et al.
Publicado: (2021)

Outpatient percutaneous native renal biopsy: safety profile in a large monocentric cohort
por: Roccatello, Dario, et al.
Publicado: (2017)

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
por: van de Donk, Niels W. C. J., et al.
Publicado: (2016)

Long-term effects of intensive B cell depletion therapy in severe cases of IgG4-related disease with renal involvement
por: Quattrocchio, Giacomo, et al.
Publicado: (2020)

The need for kidney biopsy in the management of side effects of target and immunotherapy
por: Fenoglio, Roberta, et al.
Publicado: (2023)

De Novo AL Amyloidosis in Renal Allograft and Anti-CD38 Monoclonal Antibody Treatment
por: Fotiou, Despina, et al.
Publicado: (2021)

Monoclonal Gammopathy of Renal Significance: Clinical and Histological Efficacy of a Bortezomib-Based Regimen
por: Quattrocchio, Giacomo, et al.
Publicado: (2020)

Dickkopf Homolog 3 (DKK3) as a Prognostic Marker in Lupus Nephritis: A Prospective Monocentric Experience
por: Sciascia, Savino, et al.
Publicado: (2022)

Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome
por: Fenoglio, Roberta, et al.
Publicado: (2018)

Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors
por: Horenstein, Alberto L., et al.
Publicado: (2018)

Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
por: Zannetti, Beatrice Anna, et al.
Publicado: (2020)

Daratumumab monotherapy for refractory lupus nephritis
por: Roccatello, Dario, et al.
Publicado: (2023)

The CD38/CD157 mammalian gene family: An evolutionary paradigm for other leukocyte surface enzymes
por: Deaglio, Silvia, et al.
Publicado: (2006)

Anti CD38 monoclonal antibodies for multiple myeloma treatment
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation
por: Costa, Federica, et al.
Publicado: (2017)

Chasing the Zebra: a case of membranous-like Glomerulopathy with SSA/RO52 deposits and no overt connective tissue disease
por: Sciascia, Savino, et al.
Publicado: (2023)

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
por: Morandi, Fabio, et al.
Publicado: (2018)

Vedolizumab for the Management of Refractory Behçet’s Disease: From a Case Report to New Pieces of Mosaic in a Complex Disease
por: Arbrile, Marta, et al.
Publicado: (2021)

A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes
por: Horenstein, Alberto L, et al.
Publicado: (2013)

Transfusion management for patients taking an anti-CD38 monoclonal antibody
por: Bub, Carolina Bonet, et al.
Publicado: (2018)

Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
por: Wu, Hao-Tian, et al.
Publicado: (2022)

Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38(+) tumors in mouse models in vivo
por: Fumey, William, et al.
Publicado: (2017)

Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies
por: Lancman, Guido, et al.
Publicado: (2018)

CD38 in Neurodegeneration and Neuroinflammation
por: Guerreiro, Serge, et al.
Publicado: (2020)

CD38 in Advanced Prostate Cancers
por: Guo, Christina, et al.
Publicado: (2021)

Characterization and phylogenetic epitope mapping of CD38 ADPR cyclase in the cynomolgus macaque
por: Ferrero, Enza, et al.
Publicado: (2004)

The Circular Life of Human CD38: From Basic Science to Clinics and Back
por: Horenstein, Alberto L., et al.
Publicado: (2020)

Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies
por: Sciascia, Savino, et al.
Publicado: (2021)

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
por: Plesner, Torben, et al.
Publicado: (2020)

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
por: Sanchez, Larysa, et al.
Publicado: (2016)

Phenotyping and Target Expression Profiling of CD34(+)/CD38(−) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
por: Blatt, Katharina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_iu1qgdca10v866b0gc5pct9f9n